While even mild anemia may be a risk factor for progression of CKD and for poor outcomes, these analyses suggest that the beneficial effects of treatment with losartan in this patient population on ESRD, ESRD or death, and proteinuria persisted in the presence of hemoglobin decrease.
(ESRD) and death by 20% in comparison with the placebo group and 23 Losartan had no effect on the rate of death or the composite
Previous Renal Studies showed that losartan reduced the incidence of doubling of serum creatinine levels, albuminuria and ESRD.
Furthermore, benefits on ESRD, ESRD or death, and proteinuria in the losartan treatment group were maintained when hemoglobin decreased. Patients with lower hemoglobin (persistent anemia and new anemia) may be at greater risk for ESRD. A significant benefit of losartan treatment was seen for these populations.
by E Ripley 2024 Cited by 55left ventricular hypertrophy by losartan versus atenolol: the losartan losartan on the lifetime incidence of ESRD and costs in mexico. Rev. Invest
Losartan reduced the incidence of doubling of serum creatinine, end-stage renal disease (ESRD), or death by 16% (P = 0.022) and reduced the risk of progression to ESRD, defined as the initiation of dialysis or transplantation, by 29% (P = 0.002). We set out to estimate the potential effect of losartan on the burden and costs associated with
WHAT IS EFFECT OF. PROTEINURIA ON RENAL. OUTCOME? Page 16. ARB (losartan) Reduces Risk of ESRD in. Diabetic Nephropathy. ESRD. Months. % w ith.
For the primary end-point, losartan treatment reduced the composite of a doubling of the baseline serum creatinine concentration, ESRD, or death
by WC Gerth 2024 Cited by 46Gerth et al: Losartan and ESRD costs. S-70. Table 2. RENAAL: Within-trial cumulative incidence of ESRD by duration of follow-up. Difference. Follow-up. Losartan.
Comments